Preferred Label : olaratumab;

UNII : TT6HN20MVF;

Details


Main resources

You can consult :


LARTRUVO (olaratumab) - New clinical trial information important to prescribing decisions
http://canadiensensante.gc.ca/recall-alert-rappel-avis/hc-sc/2019/68974a-fra.php
2019
false
false
false
Canada
French
English
drug information
prescription, nos
clinical trials as topic
Lartruvo
clinical trial
olaratumab
dataset
clinical trial
dataset
antibodies, monoclonal

---
https://www.prescrire.org/fr/3/31/58120/0/NewsDetails.aspx
2019
false
false
false
France
French
french abstract
olaratumab
coitus interruptus
antibodies, monoclonal

---
https://www.has-sante.fr/portail/jcms/c_2856039/fr/lartruvo
https://www.has-sante.fr/portail/jcms/c_2856039/fr/lartruvo-olaratumab-anticorps-monoclonal
2018
false
false
false
France
French
treatment outcome
orphan drug production
antineoplastic agents
adult
sarcoma
antineoplastic combined chemotherapy protocols
receptor, platelet-derived growth factor alpha
infusions, intravenous
olaratumab
evaluation of the transparency committee
Soft tissue sarcoma
guidelines for drug use
olaratumab
antibodies, monoclonal

---
https://www.ema.europa.eu/medicines/human/EPAR/Lartruvo
2016
false
false
false
United Kingdom
French
English
syndication feed
summary of product characteristics
package leaflet
drug evaluation
antibodies, monoclonal
olaratumab
drug approval
europe
treatment outcome
drug interactions
pregnancy
breast feeding
orphan drug production
antineoplastic agents
antineoplastic agents
adult
sarcoma
antineoplastic combined chemotherapy protocols
receptor, platelet-derived growth factor alpha
survival analysis
infusions, intravenous
product surveillance, postmarketing
drug evaluation, preclinical
olaratumab
olaratumab
antibodies, monoclonal

---
Nous contacter.
19/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.